Tuberculosis treatment and drug regimens

Tuberculosis is an airborne infectious disease treated with combination therapeutic regimens. Adherence to long-term antituberculosis therapy is crucial for maintaining adequate blood drug level. The emergence and spread of drug-resistant Mycobacterium tuberculosis strains are mainly favored by the...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cold Spring Harbor perspectives in medicine Ročník 5; číslo 5; s. a017822
Hlavní autoři: Sotgiu, Giovanni, Centis, Rosella, D'ambrosio, Lia, Migliori, Giovanni Battista
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States 01.05.2015
Témata:
Antitubercular Agents - administration & dosage
Antitubercular Agents - adverse effects
China
Diarylquinolines - administration & dosage
Diarylquinolines - adverse effects
Humans
India
Mycobacterium tuberculosis - drug effects
Nitroimidazoles - administration & dosage
Nitroimidazoles - adverse effects
Oxazoles - administration & dosage
Oxazoles - adverse effects
Tuberculosis, Multidrug-Resistant - drug therapy
USSR
China
USSR
India
ISSN:2157-1422, 2472-5412
On-line přístup:Zjistit podrobnosti o přístupu
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Tuberculosis is an airborne infectious disease treated with combination therapeutic regimens. Adherence to long-term antituberculosis therapy is crucial for maintaining adequate blood drug level. The emergence and spread of drug-resistant Mycobacterium tuberculosis strains are mainly favored by the inadequate medical management of the patients. The therapeutic approach for drug-resistant tuberculosis is cumbersome, because of the poor, expensive, less-effective, and toxic alternatives to the first-line drugs. New antituberculosis drugs (bedaquiline and delamanid) have been recently approved by the health authorities, but they cannot represent the definitive solution to the clinical management of drug-resistant tuberculosis forms, particularly in intermediate economy settings where the prevalence of drug resistance is high (China, India, and former Soviet Union countries). New research and development activities are urgently needed. Public health policies are required to preserve the new and old therapeutic options.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:2157-1422
2472-5412
DOI:10.1101/cshperspect.a017822